Press Releases

AlloSource To Highlight AlloFuse Select CM Cellular AlloGraft Matrix At North American Spine Society Annual Meeting

Centennial, Colo. — October 24, 2017 — AlloSource, one of the nation’s largest providers of cellular, cartilage, bone, skin and soft-tissue allografts to advance patient healing in surgical procedures, will highlight AlloFuse® Select CM at the North American Spine Society Annual Meeting (NASS). AlloFuse Select CM combines osteoconductive, osteoinductive, and osteogenic properties to support the initiation and nurturing of bone growth, leading to consistent spinal fusion outcomes and delivering the benefits of autograft bone without the potential drawbacks. The product engages the body’s natural healing power and can be used in a variety of spinal, neurologic, and orthopedic procedures. “AlloFuse…

AlloSource President And CEO Thomas Cycyota Receives American Association Of Tissue Banks Award

Centennial, Colo. — October 10, 2017 — AlloSource, one of the nation’s largest providers of cartilage, bone, skin, soft-tissue and cellular allografts for use in surgical procedures and wound care to advance patient healing, today announced that its President and Chief Executive Officer, Thomas Cycyota, received the Jeanne C. Mowe Distinguished Service Award from the American Association of Tissue Banks (AATB). The annual Jeanne C. Mowe Distinguished Service Award recognizes an individual who has made a significant contribution in tissue banking or transplantation, whether in research, education, or laboratory improvement, or who has served the Association or the field of…

AlloSource And Integra LifeSciences Announce Anchor Gifts To Phoenix Society For Burn Survivors’ Never Alone Campaign

Centennial, Colo. and Plainsboro, N.J. — October 5, 2017 — AlloSource, one of the nation’s largest providers of cellular and tissue allografts, and Integra LifeSciences, a leading global medical technology company, today announced anchor gift donations to the Phoenix Society for Burn Survivors’ Never Alone Campaign. The campaign is dedicated to raising money for strategic initiatives that will enable the Phoenix Society to provide a community of support, as well as resources and tools, for burn survivors and their families. The Never Alone Campaign supports burn survivors around the world by providing access to the Phoenix Society’s programs, networks and…

AlloSource Announces Milestone In Production Of Bioengineered Blood Vessels For Humacyte’s Vascular Access Phase III Clinical Trial

Centennial, Colo. – September 12, 2017 — AlloSource, one of the nation’s largest providers of cartilage, bone, skin, soft-tissue and cellular allografts for use in surgical procedures to advance patient healing, today announced a major milestone in its partnership with Humacyte. AlloSource completed production of investigational bioengineered blood vessels for Humacyte’s Phase III clinical trial. This Phase III clinical trial is investigating the potential of Humacyte’s HUMACYL® blood vessels to improve vascular access for hemodialysis patients with end-stage renal disease. The clinical trial compares the efficacy of Humacyte’s bioengineered human-tissue vessels to the current standard of synthetic vessels manufactured from…

Philadelphia Hand To Shoulder Center Of Thomas Jefferson University Announces Prospective Study On AlloWrap In The Hand And Wrist

Philadelphia, Pa. — August 8, 2017 — Researchers at the Philadelphia Hand to Shoulder Center (PHSC) of Thomas Jefferson University (TJU) today announced the initiation of a prospective, randomized trial for the treatment of tendon adhesions of the hand and wrist using AlloSource’s AlloWrap® DS, a human amniotic membrane, in conjunction with tenolysis. The study, titled A Prospective Randomized Trial Comparing Use of AlloWrap® DS Surgical Barrier with Tenolysis versus Tenolysis Alone for Treatment of Tendon Adhesions of the Hand and Wrist, aims to identify the ideal method for treating tendon adhesions in the hand and wrist. The study will…

AlloSource Releases AlloFuse Line Extentsion

Company adds AlloFuse Select CM, a cellular allograft matrix, to the AlloFuse portfolio Centennial, Colo. — August 1, 2017 — AlloSource, one of the nation’s largest providers of cartilage, bone, skin, soft-tissue, and cellular allografts to advance patient healing in surgical procedures and wound care, today announced the release of AlloFuse® Select CM, a premium addition to AlloSource’s AlloFuse portfolio. AlloFuse Select CM combines osteoconductive, osteoinductive, and osteogenic properties to initiate and nurture bone growth, delivering the benefits of autograft bone without the potential drawbacks. The product is clinically proven to activate and support bone formation and can be used…

Cross-Country Bike Ride For Organ, Eye And Tissue Donation Kicking Off At AlloSource

Cross-Country Bike Ride For Organ, Eye And Tissue Donation Kicking Off At AlloSource

Centennial, Colo. — June 30, 2017 — AlloSource, one of the nation’s largest providers of cartilage, bone, skin, soft-tissue and cellular allografts for use in surgical procedures to advance patient healing, today hosted the kickoff event for Pedal For Life’s cross-country bike ride to raise awareness for organ, eye and tissue donation. The Pedal for Life team will ride from Centennial, Colorado to Iowa City, Iowa and stop at each organ procurement organization on the way to highlight the importance of donation. Pedal For Life started this year’s ride in Centennial because of the organization’s connection to AlloSource. Pedal For…

Stryker And AlloSource Announce Collaboration To Distribute Biologics For Use In Sports Medicine Procedures

Denver, Colorado, USA – May 18, 2017 – Today at the 2017 Annual Arthroscopy Association of North America (AANA) Meeting (booth #109), Stryker’s Sports Medicine business and AlloSource® formally announced their collaboration to provide high quality, innovative biologics for use in sports medicine procedures. This collaboration is driven by the companies’ combined commitment to better serve their customers, help patients in need and fully honor the gift of tissue donation. “We believe biologics will play a critical role in advancing the field of Sports Medicine, so we are very excited about the opportunity to collaborate with AlloSource given their history…

AlloSource’s Burn Skin AlloGraft Rebranded To Pureskin

Company to feature PureSkin at the American Burn Association Annual Meeting Centennial, Colo. — March 20, 2017 — AlloSource, one of the nation’s largest providers of burn skin, cartilage, bone, soft-tissue and cellular allografts for use in surgical procedures and burn and wound care to advance patient healing, will feature its PureSkin™ human skin allograft at the 49th American Burn Association Annual Meeting. AlloSource has been a longtime leader in providing skin allografts to help patients heal from burns, and its rebranded PureSkin allograft offers clinicians a temporary biological dressing for burn patients. The product is available in both cryopreserved…

Theracell And AlloSource Announce Second Patent For Bone Fiber Technology

Demineralized Bone Fiber (DBF™) patent to expand TheraCell’s osteobiologic patent portfolio Northridge, Cali. and Centennial, Colo. — March 9, 2017 — TheraCell, a regenerative medicine company, today announced it was awarded a second patent for its demineralized bone fiber (DBF™) technology by the United States Patent and Trademark Office. The addition of U.S. Patent Number 9,572,912, titled Demineralized bone fibers having controlled geometry and shapes and methods thereof, expands TheraCell’s intellectual property portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry. TheraCell’s DBF™ technology is incorporated into two innovative demineralized cortical fiber allografts, AlloFuse® Cortical…